



## Clinical trial results:

### A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2018-004076-35 |
| Trial protocol           | ES             |
| Global end of trial date | 05 April 2022  |

#### Results information

|                                |               |
|--------------------------------|---------------|
| Result version number          | v1 (current)  |
| This version publication date  | 05 April 2023 |
| First version publication date | 05 April 2023 |

#### Trial information

##### Trial identification

|                       |                |
|-----------------------|----------------|
| Sponsor protocol code | INCB 01158-206 |
|-----------------------|----------------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

##### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Incyte Corporation   |
| Sponsor organisation address | 1801 Augustine Cutoff Drive, Wilmington, United States, 19803        |
| Public contact               | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |
| Scientific contact           | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |

Notes:

##### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |               |
|--|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 05 April 2022 |
| Is this the analysis of the primary completion data? | No            |

|                                  |               |
|----------------------------------|---------------|
| Global end of trial reached?     | Yes           |
| Global end of trial date         | 05 April 2022 |
| Was the trial ended prematurely? | Yes           |

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab subcutaneous (SC), compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Protection of trial subjects:

This study was to be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws and country-specific regulations in which the study is being conducted.

Background therapy: -

Evidence for comparator: -

|   |                   |
|---|-------------------|
| Actual start date of recruitment                          | 25 September 2019 |
| Long term follow-up planned                               | Yes               |
| Long term follow-up rationale                             | Efficacy          |
| Long term follow-up duration                              | 3 Years           |
| Independent data monitoring committee (IDMC) involvement? | No                |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                  |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Germany: 4       |
| Country: Number of subjects enrolled | Spain: 6         |
| Country: Number of subjects enrolled | United States: 5 |
| Worldwide total number of subjects   | 15               |
| EEA total number of subjects         | 10               |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |
| Children (2-11 years)                     | 0 |
| Adolescents (12-17 years)                 | 0 |

|                      |   |
|----------------------|---|
| Adults (18-64 years) | 7 |
| From 65 to 84 years  | 7 |
| 85 years and over    | 1 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study was conducted at 11 study centers in Germany, Spain, and the United States.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| <b>Arm title</b>             | Phase 1: INCB001158 75 mg BID + daratumumab |

Arm description:

In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | daratumumab SC                         |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Concentrate for solution for injection |
| Routes of administration               | Subcutaneous use                       |

Dosage and administration details:

120 mg/mL daratumumab + 20 µg/mL rHuPH20 solution

|  |            |
|--|------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code |            |
| Other name                             |            |
| Pharmaceutical forms                   | Tablet     |
| Routes of administration               | Oral use   |

Dosage and administration details:

25 mg and 100 mg tablets

|                  |  |
|------------------|--|
| <b>Arm title</b> | Phase 1: INCB001158 100 mg BID + daratumumab |
|------------------|--|

Arm description:

In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | daratumumab SC                         |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Concentrate for solution for injection |
| Routes of administration               | Subcutaneous use                       |

Dosage and administration details:

120 mg/mL daratumumab + 20 µg/mL rHuPH20 solution

|  |  |
|--|--|
| Investigational medicinal product name   | INCB001158   |
| Investigational medicinal product code   |  |
| Other name   |  |
| Pharmaceutical forms   | Tablet   |
| Routes of administration   | Oral use   |
| Dosage and administration details:<br>25 mg and 100 mg tablets   |  |
| <b>Arm title</b>   | Phase 2: INCB001158 100 mg BID + daratumumab                 |
| Arm description:<br>In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.   |  |
| Arm type   | Experimental   |
| Investigational medicinal product name   | daratumumab SC   |
| Investigational medicinal product code   |  |
| Other name   |  |
| Pharmaceutical forms   | Concentrate for solution for injection                       |
| Routes of administration   | Subcutaneous use   |
| Dosage and administration details:<br>120 mg/mL daratumumab + 20 µg/mL rHuPH20 solution  |  |
| Investigational medicinal product name   | INCB001158   |
| Investigational medicinal product code   |  |
| Other name   |  |
| Pharmaceutical forms   | Tablet   |
| Routes of administration   | Oral use   |
| Dosage and administration details:<br>25 mg and 100 mg tablets   |  |
| <b>Arm title</b>   | Phase 2: daratumumab; cross over to INCB001158 + daratumumab |
| Arm description:<br>In Part 1 of Phase 2, participants received daratumumb 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal. |  |
| Arm type   | Experimental   |
| Investigational medicinal product name   | daratumumab SC   |
| Investigational medicinal product code   |  |
| Other name   |  |
| Pharmaceutical forms   | Concentrate for solution for injection                       |
| Routes of administration   | Subcutaneous use   |
| Dosage and administration details:<br>120 mg/mL daratumumab + 20 µg/mL rHuPH20 solution  |  |
| Investigational medicinal product name   | INCB001158   |
| Investigational medicinal product code   |  |
| Other name   |  |
| Pharmaceutical forms   | Tablet   |
| Routes of administration   | Oral use   |
| Dosage and administration details:<br>25 mg and 100 mg tablets   |  |
| <b>Arm title</b>   | Phase 2: INCB001158; cross over to INCB001158 +              |

## Arm description:

In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | daratumumab SC                         |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Concentrate for solution for injection |
| Routes of administration               | Subcutaneous use                       |

## Dosage and administration details:

120 mg/mL daratumumab + 20 µg/mL rHuPH20 solution

|  |            |
|--|------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code |            |
| Other name                             |            |
| Pharmaceutical forms                   | Tablet     |
| Routes of administration               | Oral use   |

## Dosage and administration details:

25 mg and 100 mg tablets

| Number of subjects in period 1 | Phase 1:<br>INCB001158 75 mg<br>BID + daratumumab | Phase 1:<br>INCB001158 100 mg<br>BID + daratumumab | Phase 2:<br>INCB001158 100<br>mg BID +<br>daratumumab |
|--------------------------------|---|--|---|
|                                |   |  |   |
| Started                        | 6   | 4  | 2   |
| Completed                      | 1   | 2  | 2   |
| Not completed                  | 5   | 2  | 0   |
| Adverse event, serious fatal   | 5   | 2  | -   |

| Number of subjects in period 1 | Phase 2:<br>daratumumab; cross<br>over to INCB001158<br>+ daratumumab | Phase 2:<br>INCB001158; cross<br>over to INCB001158<br>+ daratumumab |
|--------------------------------|---|--|
|                                |   |  |
| Started                        | 1   | 2  |
| Completed                      | 0   | 1  |
| Not completed                  | 1   | 1  |
| Adverse event, serious fatal   | 1   | 1  |

## Baseline characteristics

### Reporting groups

|                       |   |
|-----------------------|---|
| Reporting group title | Phase 1: INCB001158 75 mg BID + daratumumab |
|-----------------------|---|

Reporting group description:

In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 1: INCB001158 100 mg BID + daratumumab |
|-----------------------|--|

Reporting group description:

In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 2: INCB001158 100 mg BID + daratumumab |
|-----------------------|--|

Reporting group description:

In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 2: daratumumab; cross over to INCB001158 + daratumumab |
|-----------------------|--|

Reporting group description:

In Part 1 of Phase 2, participants received daratumumab 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.

|                       |   |
|-----------------------|---|
| Reporting group title | Phase 2: INCB001158; cross over to INCB001158 + daratumumab |
|-----------------------|---|

Reporting group description:

In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.

| Reporting group values   | Phase 1:<br>INCB001158 75 mg<br>BID + daratumumab | Phase 1:<br>INCB001158 100 mg<br>BID + daratumumab | Phase 2:<br>INCB001158 100<br>mg BID +<br>daratumumab |
|--|---|--|---|
| Number of subjects   | 6   | 4  | 2   |
| Age categorical<br>Units: Subjects   |   |  |   |
| Adults (18-64 years)   | 3   | 2  | 1   |
| From 65-84 years   | 3   | 2  | 1   |
| 85 years and over  | 0   | 0  | 0   |
| Age Continuous   |   |  |   |
| 100=To protect participant privacy, a mean age and standard deviation are not reported for a single participant. |   |  |   |
| Units: years<br>arithmetic mean  | 65.0  | 68.0   | 67.0  |

|                    |         |        |         |
|--------------------|---------|--------|---------|
| standard deviation | ± 11.70 | ± 9.83 | ± 12.73 |
|--------------------|---------|--------|---------|

|   |   |   |   |
|---|---|---|---|
| Sex: Female, Male<br>Units: participants  |   |   |   |
| Female                                    | 2 | 2 | 1 |
| Male                                      | 4 | 2 | 1 |
| Race (NIH/OMB)<br>Units: Subjects         |   |   |   |
| American Indian or Alaska Native          | 0 | 0 | 0 |
| Asian                                     | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American                 | 1 | 0 | 0 |
| White                                     | 5 | 4 | 2 |
| More than one race                        | 0 | 0 | 0 |
| Unknown or Not Reported                   | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)<br>Units: Subjects    |   |   |   |
| Hispanic or Latino                        | 0 | 0 | 0 |
| Not Hispanic or Latino                    | 6 | 4 | 2 |
| Unknown or Not Reported                   | 0 | 0 | 0 |

| Reporting group values   | Phase 2:<br>daratumumab; cross<br>over to INCB001158<br>+ daratumumab | Phase 2:<br>INCB001158; cross<br>over to INCB001158<br>+ daratumumab | Total |
|--|---|--|-------|
| Number of subjects   | 1   | 2  | 15    |
| Age categorical<br>Units: Subjects   |   |  |       |
| Adults (18-64 years)   | 0   | 1  | 7     |
| From 65-84 years   | 1   | 0  | 7     |
| 85 years and over  | 0   | 1  | 1     |
| Age Continuous   |   |  |       |
| 100=To protect participant privacy, a mean age and standard deviation are not reported for a single participant. |   |  |       |
| Units: years   |   |  |       |
| arithmetic mean  | 100   | 71.5   |       |
| standard deviation   | ± 100   | ± 19.09  | -     |
| Sex: Female, Male<br>Units: participants   |   |  |       |
| Female   | 0   | 0  | 5     |
| Male   | 1   | 2  | 10    |
| Race (NIH/OMB)<br>Units: Subjects  |   |  |       |
| American Indian or Alaska Native   | 0   | 0  | 0     |
| Asian  | 0   | 0  | 0     |
| Native Hawaiian or Other Pacific Islander  | 0   | 0  | 0     |
| Black or African American  | 0   | 0  | 1     |
| White  | 1   | 2  | 14    |
| More than one race   | 0   | 0  | 0     |
| Unknown or Not Reported  | 0   | 0  | 0     |



|                         |   |   |    |
|-------------------------|---|---|----|
| Ethnicity (NIH/OMB)     |   |   |    |
| Units: Subjects         |   |   |    |
| Hispanic or Latino      | 0 | 1 | 1  |
| Not Hispanic or Latino  | 1 | 1 | 14 |
| Unknown or Not Reported | 0 | 0 | 0  |

## End points

### End points reporting groups

|  |  |
|--|--|
| Reporting group title  | Phase 1: INCB001158 75 mg BID + daratumumab                  |
| Reporting group description:<br>In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.   |  |
| Reporting group title  | Phase 1: INCB001158 100 mg BID + daratumumab                 |
| Reporting group description:<br>In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.   |  |
| Reporting group title  | Phase 2: INCB001158 100 mg BID + daratumumab                 |
| Reporting group description:<br>In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.   |  |
| Reporting group title  | Phase 2: daratumumab; cross over to INCB001158 + daratumumab |
| Reporting group description:<br>In Part 1 of Phase 2, participants received daratumumab 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal. |  |
| Reporting group title  | Phase 2: INCB001158; cross over to INCB001158 + daratumumab  |
| Reporting group description:<br>In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.   |  |

### Primary: Phase 1: Number of participants with any treatment-emergent adverse event (TEAE)

|  |  |
|--|--|
| End point title  | Phase 1: Number of participants with any treatment-emergent adverse event (TEAE) <sup>[1][2]</sup> |
| End point description:<br>A TEAE was defined as an adverse event (AE) that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment. |  |
| End point type   | Primary  |
| End point timeframe:<br>up to 454 days   |  |

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Statistical analysis was not conducted for this endpoint.

| End point values            | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab |  |  |
|-----------------------------|--|---|--|--|
| Subject group type          | Reporting group                                      | Reporting group                                       |  |  |
| Number of subjects analysed | 6  | 4   |  |  |
| Units: participants         | 6  | 4   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Phase 2: Overall Response Rate (ORR): number of participants with a documented response of complete response (CR), stringent CR (sCR), very good partial response (VGPR), or PR, as per International Myeloma Working Group (IMWG) criteria

|                 |   |
|-----------------|---|
| End point title | Phase 2: Overall Response Rate (ORR): number of participants with a documented response of complete response (CR), stringent CR (sCR), very good partial response (VGPR), or PR, as per International Myeloma Working Group (IMWG) criteria <sup>[3]</sup> <sup>[4]</sup> |
|-----------------|---|

End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

up to Day 386

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values            | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |
|-----------------------------|---|--|---|--|
| Subject group type          | Reporting group                                       | Reporting group  | Reporting group   |  |
| Number of subjects analysed | 2   | 1  | 2   |  |
| Units: participants         | 0   | 0  | 0   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: ORR: number of participants with a documented response of CR, sCR, VGPR, or PR, as per IMWG criteria

|                 |  |
|-----------------|--|
| End point title | Phase 1: ORR: number of participants with a documented response of CR, sCR, VGPR, or PR, as per IMWG criteria <sup>[5]</sup> |
|-----------------|--|

End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to Day 395

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Statistical analysis was not conducted for this endpoint.

| End point values            | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab |  |  |
|-----------------------------|--|---|--|--|
| Subject group type          | Reporting group                                      | Reporting group                                       |  |  |
| Number of subjects analysed | 6  | 4   |  |  |
| Units: participants         | 0  | 0   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2: Number of participants with any TEAE

|                 |  |
|-----------------|--|
| End point title | Phase 2: Number of participants with any TEAE <sup>[6]</sup> |
|-----------------|--|

End point description:

A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 420 days

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Statistical analysis was not conducted for this endpoint.

| End point values            | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |
|-----------------------------|---|--|---|--|
| Subject group type          | Reporting group                                       | Reporting group  | Reporting group   |  |
| Number of subjects analysed | 2   | 1  | 2   |  |
| Units: participants         | 1   | 1  | 1   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Time to response, defined as the time from the first dose of study drug to the first documented response of PR or better (CR, sCR, VGPR, or PR), as per IMWG criteria

|                 |   |
|-----------------|---|
| End point title | Phase 1: Time to response, defined as the time from the first dose of study drug to the first documented response of PR or better (CR, sCR, VGPR, or PR), as per IMWG criteria <sup>[7]</sup> |
|-----------------|---|

End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to Day 395

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Statistical analysis was not conducted for this endpoint.

| End point values                 | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab |  |  |
|----------------------------------|--|---|--|--|
| Subject group type               | Reporting group                                      | Reporting group                                       |  |  |
| Number of subjects analysed      | 0 <sup>[8]</sup>                                     | 0 <sup>[9]</sup>                                      |  |  |
| Units: days                      |  |   |  |  |
| median (confidence interval 95%) | ( to )   | ( to )  |  |  |

Notes:

[8] - No participants had a response of PR or better; thus, analysis was not conducted.

[9] - No participants had a response of PR or better; thus, analysis was not conducted.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2: Time to response, defined as the time from the first dose of study drug to the first documented response of PR or better (CR, sCR, VGPR, or PR), as per IMWG criteria

|                 |  |
|-----------------|--|
| End point title | Phase 2: Time to response, defined as the time from the first dose of study drug to the first documented response of PR or better (CR, sCR, VGPR, or PR), as per IMWG criteria <sup>[10]</sup> |
|-----------------|--|

End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to Day 386

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values                 | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |
|----------------------------------|---|--|---|--|
| Subject group type               | Reporting group                                       | Reporting group  | Reporting group   |  |
| Number of subjects analysed      | 0 <sup>[11]</sup>                                     | 0 <sup>[12]</sup>  | 0 <sup>[13]</sup>   |  |
| Units: days                      |   |  |   |  |
| median (confidence interval 95%) | ( to )  | ( to )   | ( to )  |  |

Notes:

[11] - No participants had a response of PR or better; thus, analysis was not conducted.

[12] - No participants had a response of PR or better; thus, analysis was not conducted

[13] - No participants had a response of PR or better; thus, analysis was not conducted

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Duration of response, defined as time from first documented response of PR or better (CR, sCR, VGPR, PR), as per IMWG criteria, until date of

**disease progression or death, whichever occurred first**

|                 |   |
|-----------------|---|
| End point title | Phase 1: Duration of response, defined as time from first documented response of PR or better (CR, sCR, VGPR, PR), as per IMWG criteria, until date of disease progression or death, whichever occurred first <sup>[14]</sup> |
|-----------------|---|

## End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

up to Day 395

## Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values                 | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab |  |  |
|----------------------------------|--|---|--|--|
| Subject group type               | Reporting group                                      | Reporting group                                       |  |  |
| Number of subjects analysed      | 0 <sup>[15]</sup>                                    | 0 <sup>[16]</sup>                                     |  |  |
| Units: days                      |  |   |  |  |
| median (confidence interval 95%) | ( to )   | ( to )  |  |  |

## Notes:

[15] - No participants had a response of PR or better; thus, analysis was not conducted

[16] - No participants had a response of PR or better; thus, analysis was not conducted

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Phase 2: Duration of response, defined as time from first documented response of PR or better (CR, sCR, VGPR, PR), as per IMWG criteria, until date of disease progression or death, whichever occurred first**

|                 |   |
|-----------------|---|
| End point title | Phase 2: Duration of response, defined as time from first documented response of PR or better (CR, sCR, VGPR, PR), as per IMWG criteria, until date of disease progression or death, whichever occurred first <sup>[17]</sup> |
|-----------------|---|

## End point description:

CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% bone marrow plasma cells (PCs). sCR: defined CR, plus (a) normal free light chain (FLC) ratio, (b) no clonal PCs by immunohistochemistry, immunofluorescence, or 2- to 4-color flow cytometry. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis, or ≥90% reduction in serum M-protein (SMP) plus urine M-protein (UMP) <100 milligrams (mg)/24 hours. PR: ≥50% reduction of SMP and reduction in 24-hour UMP by ≥90% or to <200 mg/24 hours. SMP and UMP not measurable: decrease of ≥50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. SMP and UMP not measurable, and serum free light assay is not measurable: ≥50% reduction in bone marrow PCs is required in place of M-protein, if Baseline bone marrow PC percentage was ≥30%. If present at Baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is required.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to Day 386

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values                 | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |
|----------------------------------|---|--|---|--|
| Subject group type               | Reporting group                                       | Reporting group  | Reporting group   |  |
| Number of subjects analysed      | 0 <sup>[18]</sup>                                     | 0 <sup>[19]</sup>  | 0 <sup>[20]</sup>   |  |
| Units: days                      |   |  |   |  |
| median (confidence interval 95%) | ( to )  | ( to )   | ( to )  |  |

Notes:

[18] - No participants had a response of PR or better; thus, analysis was not conducted.

[19] - No participants had a response of PR or better; thus, analysis was not conducted.

[20] - No participants had a response of PR or better; thus, analysis was not conducted.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-free survival (PFS), defined as the duration from the date of the first dose of study drug until either progressive disease, as per IMWG criteria, or death, whichever occurred first

|                 |   |
|-----------------|---|
| End point title | Progression-free survival (PFS), defined as the duration from the date of the first dose of study drug until either progressive disease, as per IMWG criteria, or death, whichever occurred first |
|-----------------|---|

End point description:

Progressive disease: increase of 25% from the lowest response value in any one of the following: (a) serum M-component (absolute increase must be  $\geq 0.5$  grams per deciliter [g/dL]); (b) urine M-component (absolute increase must be  $\geq 200$  mg/24 hours); (c) only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be  $> 10$  mg/dL); (d) only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell (PC) percentage (absolute percentage must be  $\geq 10\%$ ); (d) bone marrow PC percentage: the absolute percentage must be  $> 10\%$ ; (e) definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; (f) development of hypercalcemia (corrected serum calcium  $> 11.5$  mg/dL) that can be attributed solely to the PC proliferative disorder.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to approximately 2 years



| End point values            | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab |
|-----------------------------|--|---|---|--|
| Subject group type          | Reporting group                                      | Reporting group                                       | Reporting group                                       | Reporting group  |
| Number of subjects analysed | 6 <sup>[21]</sup>                                    | 4 <sup>[22]</sup>                                     | 2 <sup>[23]</sup>                                     | 1 <sup>[24]</sup>  |
| Units: days                 |  |   |   |  |
| Minimum value, uncensored   | 8  | 26  | 9999  | 9999   |
| Maximum value, uncensored   | 337  | 169   | 9999  | 9999   |

Notes:

[21] - PFS was calculated for individual participants; no formal analysis due to a small sample size.

[22] - PFS was calculated for individual participants; no formal analysis due to a small sample size.

[23] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

[24] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

| End point values            | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |  |  |
|-----------------------------|---|--|--|--|
| Subject group type          | Reporting group   |  |  |  |
| Number of subjects analysed | 2 <sup>[25]</sup>   |  |  |  |
| Units: days                 |   |  |  |  |
| Minimum value, uncensored   | 9999  |  |  |  |
| Maximum value, uncensored   | 9999  |  |  |  |

Notes:

[25] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Minimal residual disease (MRD), defined as the percentage of MRD-negative participants

|                 |   |
|-----------------|---|
| End point title | Phase 1: Minimal residual disease (MRD), defined as the percentage of MRD-negative participants <sup>[26]</sup> |
|-----------------|---|

End point description:

Bone marrow aspirate was to be collected for MRD analysis. The MRD assay required an analysis to be performed at Baseline and another analysis to be performed at the time of suspected complete response. At the time enrollment was halted, no participants had a complete response; thus, MRD analysis was not performed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to approximately 2 years

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

|                                   |  |   |  |  |
|-----------------------------------|--|---|--|--|
| <b>End point values</b>           | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab |  |  |
| Subject group type                | Reporting group                                      | Reporting group                                       |  |  |
| Number of subjects analysed       | 0 <sup>[27]</sup>                                    | 0 <sup>[28]</sup>                                     |  |  |
| Units: percentage of participants |  |   |  |  |

Notes:

[27] - Analysis was not conducted; no participants had a complete response at time of enrollment halt.

[28] - Analysis was not conducted; no participants had a complete response at time of enrollment halt.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: MRD, defined as the percentage of MRD-negative participants

|                 |  |
|-----------------|--|
| End point title | Phase 2: MRD, defined as the percentage of MRD-negative participants <sup>[29]</sup> |
|-----------------|--|

End point description:

Bone marrow aspirate was to be collected for MRD analysis. The MRD assay required an analysis to be performed at Baseline and another analysis to be performed at the time of suspected complete response. At the time enrollment was halted, no participants had a complete response; thus, MRD analysis was not performed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to approximately 2 years

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

|                                   |   |  |   |  |
|-----------------------------------|---|--|---|--|
| <b>End point values</b>           | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |
| Subject group type                | Reporting group                                       | Reporting group  | Reporting group   |  |
| Number of subjects analysed       | 0 <sup>[30]</sup>                                     | 0 <sup>[31]</sup>  | 0 <sup>[32]</sup>   |  |
| Units: percentage of participants |   |  |   |  |

Notes:

[30] - Analysis was not conducted; no participants had a complete response at time of enrollment halt.

[31] - Analysis was not conducted; no participants had a complete response at time of enrollment halt.

[32] - Analysis was not conducted; no participants had a complete response at time of enrollment halt.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall survival

|                 |                  |
|-----------------|------------------|
| End point title | Overall survival |
|-----------------|------------------|

End point description:

Overall survival (OS) was defined as the time from the first dose of study drug to death from any cause until study completion. 9999=Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:  
up to 923 days (approximately 2.5 years)

| End point values            | Phase 1:<br>INCB001158<br>75 mg BID +<br>daratumumab | Phase 1:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>INCB001158<br>100 mg BID +<br>daratumumab | Phase 2:<br>daratumumab;<br>cross over to<br>INCB001158 +<br>daratumumab |
|-----------------------------|--|---|---|--|
| Subject group type          | Reporting group                                      | Reporting group                                       | Reporting group                                       | Reporting group  |
| Number of subjects analysed | 6 <sup>[33]</sup>                                    | 4 <sup>[34]</sup>                                     | 2 <sup>[35]</sup>                                     | 1 <sup>[36]</sup>  |
| Units: days                 |  |   |   |  |
| number (not applicable)     |  |   |   |  |
| Minimum value, uncensored   | 113  | 127   | 9999  | 9999   |
| Maximum value, uncensored   | 766  | 604   | 9999  | 9999   |

Notes:

[33] - OS was calculated for individual participants; no formal analysis due to a small sample size.

[34] - OS was calculated for individual participants; no formal analysis due to a small sample size.

[35] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

[36] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

| End point values            | Phase 2:<br>INCB001158;<br>cross over to<br>INCB001158 +<br>daratumumab |  |  |  |
|-----------------------------|---|--|--|--|
| Subject group type          | Reporting group   |  |  |  |
| Number of subjects analysed | 2 <sup>[37]</sup>   |  |  |  |
| Units: days                 |   |  |  |  |
| number (not applicable)     |   |  |  |  |
| Minimum value, uncensored   | 9999  |  |  |  |
| Maximum value, uncensored   | 9999  |  |  |  |

Notes:

[37] - Data cannot be reported; the small sample size could lead to the re-identification of participants.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were assessed for up to 454 days; All-cause Mortality was assessed for up to 923 days (approximately 2.5 years).

Adverse event reporting additional description:

Treatment-emergent adverse events (TEAEs), defined as adverse events that were reported for the first time or the worsening of pre-existing events after the first dose of study treatment, have been reported.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

### Reporting groups

|                       |   |
|-----------------------|---|
| Reporting group title | Phase 1: INCB001158 75 mg BID + daratumumab |
|-----------------------|---|

Reporting group description:

In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 1: INCB001158 100 mg BID + daratumumab |
|-----------------------|--|

Reporting group description:

In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

|                       |       |
|-----------------------|-------|
| Reporting group title | Total |
|-----------------------|-------|

Reporting group description:

Total

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 1/2: daratumumab; cross over to INCB001158 + daratumumab |
|-----------------------|--|

Reporting group description:

In Phase 1, participants received daratumumab 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Phase 2 to receive oral INCB001158 75 or 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.

|                       |   |
|-----------------------|---|
| Reporting group title | Phase 1/2: INCB001158; cross over to INCB001158 + daratumumab |
|-----------------------|---|

Reporting group description:

In Phase 1, participants received oral INCB001158 75 or 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 to receive oral INCB001158 75 or 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not meet any criteria for study withdrawal.

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 2: INCB001158 100 mg BID + daratumumab |
|-----------------------|--|

Reporting group description:

In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.

| <b>Serious adverse events</b>                        | Phase 1:<br>INCB001158 75 mg<br>BID + daratumumab | Phase 1:<br>INCB001158 100 mg<br>BID + daratumumab | Total           |
|--|---|--|-----------------|
| Total subjects affected by serious adverse events    |   |  |                 |
| subjects affected / exposed                          | 3 / 6 (50.00%)                                    | 1 / 4 (25.00%)                                     | 5 / 15 (33.33%) |
| number of deaths (all causes)                        | 5   | 2  | 9               |
| number of deaths resulting from adverse events       | 0   | 0  | 0               |
| Cardiac disorders                                    |   |  |                 |
| Atrial fibrillation                                  |   |  |                 |
| subjects affected / exposed                          | 1 / 6 (16.67%)                                    | 0 / 4 (0.00%)                                      | 1 / 15 (6.67%)  |
| occurrences causally related to treatment / all      | 0 / 2   | 0 / 0  | 0 / 2           |
| deaths causally related to treatment / all           | 0 / 0   | 0 / 0  | 0 / 0           |
| General disorders and administration site conditions |   |  |                 |
| Condition aggravated                                 |   |  |                 |
| subjects affected / exposed                          | 1 / 6 (16.67%)                                    | 0 / 4 (0.00%)                                      | 1 / 15 (6.67%)  |
| occurrences causally related to treatment / all      | 0 / 1   | 0 / 0  | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0   | 0 / 0  | 0 / 0           |
| Fatigue  |   |  |                 |
| subjects affected / exposed                          | 0 / 6 (0.00%)                                     | 1 / 4 (25.00%)                                     | 1 / 15 (6.67%)  |
| occurrences causally related to treatment / all      | 0 / 0   | 0 / 1  | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0   | 0 / 0  | 0 / 0           |
| Pain   |   |  |                 |
| subjects affected / exposed                          | 0 / 6 (0.00%)                                     | 1 / 4 (25.00%)                                     | 1 / 15 (6.67%)  |
| occurrences causally related to treatment / all      | 0 / 0   | 0 / 1  | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0   | 0 / 0  | 0 / 0           |
| Gastrointestinal disorders                           |   |  |                 |
| Constipation   |   |  |                 |
| subjects affected / exposed                          | 1 / 6 (16.67%)                                    | 0 / 4 (0.00%)                                      | 1 / 15 (6.67%)  |
| occurrences causally related to treatment / all      | 0 / 1   | 0 / 0  | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0   | 0 / 0  | 0 / 0           |
| Psychiatric disorders                                |   |  |                 |
| Delirium   |   |  |                 |

|   |                |               |                |
|---|----------------|---------------|----------------|
| subjects affected / exposed                     | 1 / 6 (16.67%) | 0 / 4 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| <b>Infections and infestations</b>              |                |               |                |
| Pneumonia                                       |                |               |                |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 0 / 4 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| <b>Metabolism and nutrition disorders</b>       |                |               |                |
| Type 2 diabetes mellitus                        |                |               |                |
| subjects affected / exposed                     | 1 / 6 (16.67%) | 0 / 4 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |

| <b>Serious adverse events</b>                               | Phase 1/2:<br>daratumumab; cross<br>over to INCB001158<br>+ daratumumab | Phase 1/2:<br>INCB001158; cross<br>over to INCB001158<br>+ daratumumab | Phase 2:<br>INCB001158 100<br>mg BID +<br>daratumumab |
|---|---|--|---|
| <b>Total subjects affected by serious adverse events</b>    |   |  |   |
| subjects affected / exposed                                 | 1 / 1 (100.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)   |
| number of deaths (all causes)                               | 1   | 1  | 0   |
| number of deaths resulting from adverse events              | 0   | 0  | 0   |
| <b>Cardiac disorders</b>                                    |   |  |   |
| Atrial fibrillation   |   |  |   |
| subjects affected / exposed                                 | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to treatment / all             | 0 / 0   | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0   | 0 / 0  | 0 / 0   |
| <b>General disorders and administration site conditions</b> |   |  |   |
| Condition aggravated  |   |  |   |
| subjects affected / exposed                                 | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to treatment / all             | 0 / 0   | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0   | 0 / 0  | 0 / 0   |
| Fatigue   |   |  |   |
| subjects affected / exposed                                 | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to treatment / all             | 0 / 0   | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0   | 0 / 0  | 0 / 0   |
| Pain  |   |  |   |

|   |                 |               |               |
|---|-----------------|---------------|---------------|
| subjects affected / exposed                     | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0         | 0 / 0         |
| <b>Gastrointestinal disorders</b>               |                 |               |               |
| Constipation                                    |                 |               |               |
| subjects affected / exposed                     | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0         | 0 / 0         |
| <b>Psychiatric disorders</b>                    |                 |               |               |
| Delirium  |                 |               |               |
| subjects affected / exposed                     | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0         | 0 / 0         |
| <b>Infections and infestations</b>              |                 |               |               |
| Pneumonia                                       |                 |               |               |
| subjects affected / exposed                     | 1 / 1 (100.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0         | 0 / 0         |
| <b>Metabolism and nutrition disorders</b>       |                 |               |               |
| Type 2 diabetes mellitus                        |                 |               |               |
| subjects affected / exposed                     | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0         | 0 / 0         |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Phase 1:<br>INCB001158 75 mg<br>BID + daratumumab | Phase 1:<br>INCB001158 100 mg<br>BID + daratumumab | Total            |
|---|---|--|------------------|
| Total subjects affected by non-serious adverse events |   |  |                  |
| subjects affected / exposed                           | 6 / 6 (100.00%)                                   | 4 / 4 (100.00%)                                    | 13 / 15 (86.67%) |
| <b>Vascular disorders</b>                             |   |  |                  |
| Flushing  |   |  |                  |
| subjects affected / exposed                           | 0 / 6 (0.00%)                                     | 0 / 4 (0.00%)                                      | 1 / 15 (6.67%)   |
| occurrences (all)                                     | 0   | 0  | 1                |
| Hypertension  |   |  |                  |

|   |                    |                     |                     |
|---|--------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)        | 0 / 6 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1 |
| General disorders and administration<br>site conditions |                    |                     |                     |
| Asthenia  |                    |                     |                     |
| subjects affected / exposed                             | 0 / 6 (0.00%)      | 1 / 4 (25.00%)      | 4 / 15 (26.67%)     |
| occurrences (all)                                       | 0                  | 1                   | 4                   |
| Discomfort  |                    |                     |                     |
| subjects affected / exposed                             | 0 / 6 (0.00%)      | 1 / 4 (25.00%)      | 1 / 15 (6.67%)      |
| occurrences (all)                                       | 0                  | 1                   | 1                   |
| Fatigue   |                    |                     |                     |
| subjects affected / exposed                             | 3 / 6 (50.00%)     | 0 / 4 (0.00%)       | 4 / 15 (26.67%)     |
| occurrences (all)                                       | 3                  | 0                   | 4                   |
| Injection site bruising                                 |                    |                     |                     |
| subjects affected / exposed                             | 1 / 6 (16.67%)     | 0 / 4 (0.00%)       | 1 / 15 (6.67%)      |
| occurrences (all)                                       | 1                  | 0                   | 1                   |
| Oedema peripheral                                       |                    |                     |                     |
| subjects affected / exposed                             | 1 / 6 (16.67%)     | 1 / 4 (25.00%)      | 3 / 15 (20.00%)     |
| occurrences (all)                                       | 1                  | 1                   | 3                   |
| Pyrexia   |                    |                     |                     |
| subjects affected / exposed                             | 0 / 6 (0.00%)      | 1 / 4 (25.00%)      | 2 / 15 (13.33%)     |
| occurrences (all)                                       | 0                  | 1                   | 3                   |
| Respiratory, thoracic and mediastinal<br>disorders      |                    |                     |                     |
| Cough   |                    |                     |                     |
| subjects affected / exposed                             | 1 / 6 (16.67%)     | 0 / 4 (0.00%)       | 2 / 15 (13.33%)     |
| occurrences (all)                                       | 1                  | 0                   | 2                   |
| Dyspnoea  |                    |                     |                     |
| subjects affected / exposed                             | 1 / 6 (16.67%)     | 0 / 4 (0.00%)       | 2 / 15 (13.33%)     |
| occurrences (all)                                       | 1                  | 0                   | 2                   |
| Lung infiltration                                       |                    |                     |                     |
| subjects affected / exposed                             | 1 / 6 (16.67%)     | 0 / 4 (0.00%)       | 1 / 15 (6.67%)      |
| occurrences (all)                                       | 1                  | 0                   | 1                   |
| Nasal congestion  |                    |                     |                     |
| subjects affected / exposed                             | 2 / 6 (33.33%)     | 0 / 4 (0.00%)       | 2 / 15 (13.33%)     |
| occurrences (all)                                       | 2                  | 0                   | 2                   |
| Productive cough  |                    |                     |                     |



|   |                     |                     |                      |
|---|---------------------|---------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 2 / 15 (13.33%)<br>2 |
| Pulmonary oedema<br>subjects affected / exposed<br>occurrences (all)  | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Psychiatric disorders<br>Depression<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Listless<br>subjects affected / exposed<br>occurrences (all)  | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Investigations<br>Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Injury, poisoning and procedural complications<br>Clavicle fracture<br>subjects affected / exposed<br>occurrences (all) | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Humerus fracture<br>subjects affected / exposed<br>occurrences (all)  | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Rib fracture<br>subjects affected / exposed<br>occurrences (all)  | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)   | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Cardiac disorders<br>Cardiac failure<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |

|   |                     |                     |                      |
|---|---------------------|---------------------|----------------------|
| Cardiovascular insufficiency<br>subjects affected / exposed<br>occurrences (all)  | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Nervous system disorders  |                     |                     |                      |
| Dysaesthesia<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Dysstasia<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 2 / 15 (13.33%)<br>2 |
| Hypoaesthesia<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)         | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Peripheral sensory neuropathy<br>subjects affected / exposed<br>occurrences (all) | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Blood and lymphatic system disorders  |                     |                     |                      |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>4  |
| Lymphopenia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1  |
| Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all)              | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 3 / 15 (20.00%)<br>3 |
| Gastrointestinal disorders  |                     |                     |                      |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)                | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1  |
| Constipation  |                     |                     |                      |

|   |                |                |                 |
|---|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 1 / 4 (25.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 1              | 1               |
| Diarrhoea                                       |                |                |                 |
| subjects affected / exposed                     | 3 / 6 (50.00%) | 0 / 4 (0.00%)  | 3 / 15 (20.00%) |
| occurrences (all)                               | 3              | 0              | 3               |
| Dyspepsia                                       |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 1 / 4 (25.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 1              | 1               |
| Nausea  |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 2 / 4 (50.00%) | 2 / 15 (13.33%) |
| occurrences (all)                               | 0              | 2              | 2               |
| Skin and subcutaneous tissue disorders          |                |                |                 |
| Alopecia  |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 1 / 4 (25.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 1              | 1               |
| Ingrowing nail                                  |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 0 / 4 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Pruritus  |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 0 / 4 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Musculoskeletal and connective tissue disorders |                |                |                 |
| Arthralgia                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 0 / 4 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Bone pain                                       |                |                |                 |
| subjects affected / exposed                     | 1 / 6 (16.67%) | 0 / 4 (0.00%)  | 2 / 15 (13.33%) |
| occurrences (all)                               | 1              | 0              | 2               |
| Muscle spasms                                   |                |                |                 |
| subjects affected / exposed                     | 1 / 6 (16.67%) | 0 / 4 (0.00%)  | 2 / 15 (13.33%) |
| occurrences (all)                               | 1              | 0              | 2               |
| Muscular weakness                               |                |                |                 |
| subjects affected / exposed                     | 0 / 6 (0.00%)  | 1 / 4 (25.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 1              | 1               |
| Musculoskeletal chest pain                      |                |                |                 |

|   |                     |                     |                     |
|---|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1 |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1 |
| Infections and infestations<br>Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)    | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1 |
| Oral candidiasis<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Rhinovirus infection<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 6 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Tooth infection<br>subjects affected / exposed<br>occurrences (all)                                   | 1 / 6 (16.67%)<br>2 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>2 |
| Metabolism and nutrition disorders<br>Dehydration<br>subjects affected / exposed<br>occurrences (all) | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)                                    | 1 / 6 (16.67%)<br>1 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Hypophosphataemia<br>subjects affected / exposed<br>occurrences (all)                                 | 1 / 6 (16.67%)<br>2 | 0 / 4 (0.00%)<br>0  | 1 / 15 (6.67%)<br>2 |
| Oroticaciduria<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 6 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 15 (6.67%)<br>1 |

|                                   |  |   |  |
|-----------------------------------|--|---|--|
| <b>Non-serious adverse events</b> | Phase 1/2:<br>daratumumab; cross<br>over to INCB001158 | Phase 1/2:<br>INCB001158; cross<br>over to INCB001158 | Phase 2:<br>INCB001158 100<br>mg BID + |
|-----------------------------------|--|---|--|

|   | + daratumumab   | + daratumumab  | daratumumab    |
|---|-----------------|----------------|----------------|
| Total subjects affected by non-serious adverse events |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 1 / 2 (50.00%) | 1 / 2 (50.00%) |
| Vascular disorders                                    |                 |                |                |
| Flushing  |                 |                |                |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 1 / 2 (50.00%) |
| occurrences (all)                                     | 0               | 0              | 1              |
| Hypertension  |                 |                |                |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 0               | 0              | 0              |
| General disorders and administration site conditions  |                 |                |                |
| Asthenia  |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 1 / 2 (50.00%) | 1 / 2 (50.00%) |
| occurrences (all)                                     | 1               | 1              | 1              |
| Discomfort  |                 |                |                |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 0               | 0              | 0              |
| Fatigue   |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 1               | 0              | 0              |
| Injection site bruising                               |                 |                |                |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 0               | 0              | 0              |
| Oedema peripheral                                     |                 |                |                |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 0 / 2 (0.00%)  | 1 / 2 (50.00%) |
| occurrences (all)                                     | 0               | 0              | 1              |
| Pyrexia   |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 2               | 0              | 0              |
| Respiratory, thoracic and mediastinal disorders       |                 |                |                |
| Cough   |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 1               | 0              | 0              |
| Dyspnoea  |                 |                |                |
| subjects affected / exposed                           | 1 / 1 (100.00%) | 0 / 2 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                                     | 1               | 0              | 0              |

|   |                      |                     |                    |
|---|----------------------|---------------------|--------------------|
| Lung infiltration<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Nasal congestion<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Productive cough<br>subjects affected / exposed<br>occurrences (all)  | 1 / 1 (100.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Pulmonary oedema<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Psychiatric disorders<br>Depression<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Listless<br>subjects affected / exposed<br>occurrences (all)  | 1 / 1 (100.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Investigations<br>Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                | 0 / 1 (0.00%)<br>0   | 1 / 2 (50.00%)<br>1 | 0 / 2 (0.00%)<br>0 |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 1 (0.00%)<br>0   | 1 / 2 (50.00%)<br>1 | 0 / 2 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Clavicle fracture<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Humerus fracture<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |
| Rib fracture<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0 |

|   |                      |                    |                     |
|---|----------------------|--------------------|---------------------|
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)               | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Cardiac disorders   |                      |                    |                     |
| Cardiac failure<br>subjects affected / exposed<br>occurrences (all)               | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Cardiovascular insufficiency<br>subjects affected / exposed<br>occurrences (all)  | 1 / 1 (100.00%)<br>1 | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Nervous system disorders  |                      |                    |                     |
| Dysaesthesia<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Dysstasia<br>subjects affected / exposed<br>occurrences (all)                     | 1 / 1 (100.00%)<br>1 | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                      | 1 / 1 (100.00%)<br>1 | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Hypoaesthesia<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)         | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Peripheral sensory neuropathy<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Blood and lymphatic system disorders  |                      |                    |                     |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 1 / 2 (50.00%)<br>4 |
| Lymphopenia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 1 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0  |
| Thrombocytopenia  |                      |                    |                     |

|  |                    |                     |                     |
|--|--------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 1 / 2 (50.00%)<br>1 | 1 / 2 (50.00%)<br>1 |
| Gastrointestinal disorders                       |                    |                     |                     |
| Abdominal pain                                   |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Constipation                                     |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Diarrhoea  |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Dyspepsia  |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Nausea   |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Skin and subcutaneous tissue disorders           |                    |                     |                     |
| Alopecia   |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 0                   | 0                   |
| Ingrowing nail                                   |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 1 / 2 (50.00%)      | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 1                   | 0                   |
| Pruritus   |                    |                     |                     |
| subjects affected / exposed                      | 1 / 1 (100.00%)    | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 1                  | 0                   | 0                   |
| Musculoskeletal and connective tissue disorders  |                    |                     |                     |
| Arthralgia                                       |                    |                     |                     |
| subjects affected / exposed                      | 1 / 1 (100.00%)    | 0 / 2 (0.00%)       | 0 / 2 (0.00%)       |
| occurrences (all)                                | 1                  | 0                   | 0                   |
| Bone pain  |                    |                     |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 1 / 2 (50.00%)      | 0 / 2 (0.00%)       |
| occurrences (all)                                | 0                  | 1                   | 0                   |
| Muscle spasms                                    |                    |                     |                     |



|                                    |                 |               |               |
|------------------------------------|-----------------|---------------|---------------|
| subjects affected / exposed        | 1 / 1 (100.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 1               | 0             | 0             |
| Muscular weakness                  |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Musculoskeletal chest pain         |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Myalgia                            |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Pain in extremity                  |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Infections and infestations        |                 |               |               |
| Nasopharyngitis                    |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Oral candidiasis                   |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Rhinovirus infection               |                 |               |               |
| subjects affected / exposed        | 1 / 1 (100.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 1               | 0             | 0             |
| Tooth infection                    |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Metabolism and nutrition disorders |                 |               |               |
| Dehydration                        |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Hyperglycaemia                     |                 |               |               |
| subjects affected / exposed        | 0 / 1 (0.00%)   | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Hypophosphataemia                  |                 |               |               |

|                             |               |               |               |
|-----------------------------|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 0             | 0             |
| Oroticaciduria              |               |               |               |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 0             | 0             |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment   |
|------------------|---|
| 11 March 2019    | <p>A summary of experimental studies was added to provide evidence to support the biologic rationale for the combination.</p> <p>Updated to allow for 2 cycles of INCB001158 monotherapy instead of 3 cycles in Treatment Group C – Part 1, and to require all participants to have had at least 3 prior treatments.</p> <p>Stopping rules were added for safety in Phase 2.</p> <p>A revision was made to clarify the definition of injection-related reactions (IRRs) and the management of IRRs.</p> |
| 12 October 2020  | <p>The primary purpose of this amendment was to introduce a crossover to INCB001158+daratumumab after daratumumab monotherapy.</p>  |
| 01 December 2021 | <p>The primary purpose of this amendment was to provide guidance for the management of ongoing participants, as enrollment had been terminated and sufficient data had been collected for safety analysis.</p>  |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated following a recruitment challenge. There were no safety-related concerns.

Notes: